PLX - Gunggung utang perusahaan protalix.com

Protalix BioTherapeutics develops innovative therapies for orphan diseases. The company's debt pricing characteristics are at 0.01. The business minimizes risks by applying plant-based cell technologies in high-margin niches. Current financial stability relies on licensing payments from the commercialization of Elfabrio while new developments undergo clinical trials.

For the long-term investor, the key reliability factor for Protalix BioTherapeutics is the control of its debt load. This metric aggregates all short-term and long-term liabilities, measuring the organization's level of financial leverage. By analyzing the history of borrowed capital, one can assess the pace of credit accumulation used to fund research and development. Moderate debt minimizes default risks even amidst regional instability in the Middle East. The humanitarian status of the products ensures business resilience regardless of the volume of borrowings.